1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108.
2005.PubMed/NCBI View Article : Google Scholar
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
3
|
Larsson SC, Orsini N and Wolk A: Processed
meat consumption and stomach cancer risk: A meta-analysis. J Natl
Cancer Inst. 98:1078–1087. 2006.PubMed/NCBI View Article : Google Scholar
|
4
|
Cirri P and Chiarugi P:
Cancer-associated-fibroblasts and tumour cells: A diabolic liaison
driving cancer progression. Cancer Metastasis Re. 31:195–208.
2012.PubMed/NCBI View Article : Google Scholar
|
5
|
Xing F, Saidou J and Watabe K: Cancer
associated fibroblasts (CAFs) in tumor microenvironment. Front
Biosci (Landmark Ed). 15:166–179. 2010.PubMed/NCBI View
Article : Google Scholar
|
6
|
Brockmann L, Giannou AD, Gagliani N and
Huber S: Regulation of TH17 cells and associated
cytokines in wound healing, tissue regeneration, and
carcinogenesis. Int J Mol Sci. 18(pii: E1033)2017.PubMed/NCBI View Article : Google Scholar
|
7
|
Vivier E, Spits H and Cupedo T:
Interleukin-22-producing innate immune cells: New players in
mucosal immunity and tissue repair? Nat Rev Immunol. 9:229–234.
2009.PubMed/NCBI View
Article : Google Scholar
|
8
|
Jiang R, Wang H, Deng L, Hou J, Shi R, Yao
M, Gao Y, Yao A, Wang X, Yu L and Sun B: IL-22 is related to
development of human colon cancer by activation of STAT3. BMC
Cancer. 13(59)2013.PubMed/NCBI View Article : Google Scholar
|
9
|
Xu X, Tang Y, Guo S, Zhang Y, Tian Y, Ni B
and Wang H: Increased intratumoral interleukin 22 levels and
frequencies of interleukin 22-producing CD4+ T cells correlate with
pancreatic cancer progression. Pancreas. 43:470–477.
2014.PubMed/NCBI View Article : Google Scholar
|
10
|
Petanidis S, Anestakis D, Argyraki M,
Hadzopoulou-Cladaras M and Salifoglou A: Differential expression of
IL-17, 22 and 23 in the progression of colorectal cancer in
patients with K-ras mutation: Ras signal inhibition and crosstalk
with GM-CSF and IFN-γ. PLoS One. 8(e73616)2013.PubMed/NCBI View Article : Google Scholar
|
11
|
Kyriakis JM, Banerjee P, Nikolakaki E, Dai
T, Rubie EA, Ahmad MF, Avruch J and Woodgett JR: The
stress-activated protein kinase subfamily of c-Jun kinases. Nature.
369:156–160. 1994.PubMed/NCBI View
Article : Google Scholar
|
12
|
Auladell C, de Lemos L, Verdaguer E,
Ettcheto M, Busquets O, Lazarowski A, Beas-Zarate C, Olloquequi J,
Folch J and Camins A: Role of JNK isoforms in the kainic acid
experimental model of epilepsy and neurodegeneration. Front Biosci
(Landmark Ed). 22:795–814. 2017.PubMed/NCBI View
Article : Google Scholar
|
13
|
Sabapathy K, Jochum W, Hochedlinger K,
Chang L, Karin M and Wagner EF: Defective neural tube morphogenesis
and altered apoptosis in the absence of both JNK1 and JNK2. Mech
Dev. 89:115–124. 1999.PubMed/NCBI View Article : Google Scholar
|
14
|
Ribas VT, Gonçalves BS, Linden R and
Chiarini LB: Activation of c-Jun N-terminal kinase (JNK) during
mitosis in retinal progenitor cells. PLoS One.
7(e34483)2012.PubMed/NCBI View Article : Google Scholar
|
15
|
Nanni M, Ranieri D, Rosato B, Torrisi MR
and Belleudi F: Role of fibroblast growth factor receptor 2b in the
cross talk between autophagy and differentiation: Involvement of
Jun N-terminal protein kinase signaling. Mol Cell Biol. 38(pii:
e00119-18)2018.PubMed/NCBI View Article : Google Scholar
|
16
|
Song N, Liu ZS, Xue W, Bai ZF, Wang QY,
Dai J, Liu X, Huang YJ, Cai H, Zhan XY, et al: NLRP3
phosphorylation is an essential priming event for inflammasome
activation. Mol Cell. 68:185–197.e6. 2007.
|
17
|
Lawan A and Bennett AM: Mitogen-activated
protein kinase regulation in hepatic metabolism. Trends Endocrinol
Metab. 28:868–878. 2017.PubMed/NCBI View Article : Google Scholar
|
18
|
Dhanasekaran DN and Reddy EP: JNK
signaling in apoptosis. Oncogene. 27:6245–6251. 2008.PubMed/NCBI View Article : Google Scholar
|
19
|
Markota A, Endres S and Kobold S:
Targeting interleukin-22 for cancer therapy. Hum Vaccin Immunother.
14:2012–2015. 2018.PubMed/NCBI View Article : Google Scholar
|
20
|
Lim C and Savan R: The role of the
IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev.
25:257–271. 2014.PubMed/NCBI View Article : Google Scholar
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)). Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
22
|
Neugut AI, Hayek M and Howe G:
Epidemiology of gastric cancer. Semin Oncol. 23:281–291.
1996.PubMed/NCBI
|
23
|
Tanizawa Y and Terashima M: Lymph node
dissection in the resection of gastric cancer: Review of existing
evidence. Gastric Cancer. 13:137–148. 2010.PubMed/NCBI View Article : Google Scholar
|
24
|
An JY, Ha TK, Noh JH, Sohn TS and Kim S:
Proposal to subclassify stage IV gastric cancer into IVA, IVB, and
IVM. Arch Surg. 144:38–45. 2009.PubMed/NCBI View Article : Google Scholar
|
25
|
Rutz S, Wang X and Ouyang W: The IL-20
subfamily of cytokines-from host defence to tissue homeostasis. Nat
Rev Immunol. 14:783–795. 2014.PubMed/NCBI View
Article : Google Scholar
|
26
|
Rolla S, Alchera E, Imarisio C, Bardina V,
Valente G, Cappello P, Mombello C, Follenzi A, Novelli F and Carini
R: The balance between IL-17 and IL-22 produced by
liver-infiltrating T-helper cells critically controls NASH
development in mice. Clin Sci (Lond). 130:193–203. 2016.PubMed/NCBI View Article : Google Scholar
|
27
|
Crome SQ, Nguyen LT, Lopez-Verges S, Yang
SY, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, et al: A
distinct innate lymphoid cell population regulates tumor-associated
T cells. Nat Med. 23:368–375. 2017.PubMed/NCBI View
Article : Google Scholar
|
28
|
Khosravi N, Caetano MS, Cumpian AM, Unver
N, De la Garza Ramos C, Noble O, Daliri S, Hernandez BJ, Gutierrez
BA, Evans SE, et al: IL22 Promotes Kras-Mutant lung cancer
by induction of a protumor immune response and protection of
stemness properties. Cancer Immunol Res. 6:788–797. 2018.PubMed/NCBI View Article : Google Scholar
|
29
|
Lejeune D, Dumoutier L, Constantinescu S,
Kruijer W, Schuringa JJ and Renauld JC: Interleukin-22 (IL-22)
activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a
rat hepatoma cell line. Pathways that are shared with and distinct
from IL-10. J Biol Chem. 277:33676–33682. 2002.PubMed/NCBI View Article : Google Scholar
|
30
|
Andoh A, Zhang Z, Inatomi O, Fujino S,
Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S,
Takayanagi A, et al: Interleukin-22, a member of the IL-10
subfamily, induces inflammatory responses in colonic subepithelial
myofibroblasts. Gastroenterology. 129:969–984. 2005.PubMed/NCBI View Article : Google Scholar
|
31
|
Mitra A, Raychaudhuri SK and Raychaudhuri
SP: IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR
signaling cascade. Cytokine. 60:38–42. 2012.PubMed/NCBI View Article : Google Scholar
|
32
|
Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko
Y, Hiromura K, Ueki K and Nojima Y: Expression of interleukin-22 in
rheumatoid arthritis: Potential role as a proinflammatory cytokine.
Arthritis Rheum. 52:1037–1046. 2005.PubMed/NCBI View Article : Google Scholar
|
33
|
Jiang R, Tan Z, Deng L, Chen Y, Xia Y, Gao
Y, Wang X and Sun B: Interleukin-22 promotes human hepatocellular
carcinoma by activation of STAT3. Hepatology. 54:900–909.
2011.PubMed/NCBI View Article : Google Scholar
|
34
|
Ji Y, Yang X, Li J, Lu Z, Li X, Yu J and
Li N: IL-22 promotes the migration and invasion of gastric cancer
cells via IL-22R1/AKT/MMP-9 signaling. Int J Clin Exp Pathol.
7:3694–3703. 2014.PubMed/NCBI
|
35
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009.PubMed/NCBI View
Article : Google Scholar
|
36
|
Leu CM, Wong FH, Chang C, Huang SF and Hu
C: Interleukin-6 acts as an antiapoptotic factor in human
esophageal carcinoma cells through the activation of both STAT3 and
mitogen-activated protein kinase pathways. Oncogene. 22:7809–7818.
2003.PubMed/NCBI View Article : Google Scholar
|